McKESSON CORPORATION REPORTS FISCAL 2024 FOURTH QUARTER AND FULL YEAR RESULTS Fourth Quarter Highlights: • Consolidated revenues of $76.4 billion increased by 11%. • Earnings per diluted share from continuing operations of $6.02 increased $0.31. • Adjusted Earnings per Diluted Share of $6.18 decreased by 14%. Full Year Highlights: • Consolidated revenues of $309.0 billion increased by 12%. • Earnings per diluted share from continuing operations of $22.39 decreased $2.66. • Adjusted Earnings per Diluted Shar ...

Wall Street analysts expect McKesson (MCK) to post quarterly earnings of $6.34 per share in its upcoming report, which indicates a year-over-year decline of 11.8%. Revenues are expected to be $78.72 billion, up 14.2% from the year-ago quarter.The consensus EPS estimate for the quarter has been revised 0.3% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Prior to a company's earnin ...

The market expects McKesson (MCK) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on May 7, 2024, might help the stock move higher if these key numbers are better th ...

McKesson (MCK) closed the latest trading day at $543.30, indicating a +0.62% change from the previous session's end. This change lagged the S&P 500's 1.02% gain on the day. Meanwhile, the Dow experienced a rise of 0.4%, and the technology-dominated Nasdaq saw an increase of 2.03%.The prescription drug distributor's stock has climbed by 0.58% in the past month, exceeding the Medical sector's loss of 5.2% and the S&P 500's loss of 3.15%.Investors will be eagerly watching for the performance of McKesson in its ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores.What are the Zacks Style Scores?Developed alon ...

McKessonCorporation (MCK) is well-poised for growth, backed by strategic collaborations and strength in the Distribution Solutions segment. However, the company’s opioid-related litigation expenses are a potential threat.Shares of this currently Zacks Rank #3 (Hold) company have risen 15.4% so far this year compared with the industry’s 6% growth. The S&P 500 Index has jumped 9.6% in the same time frame.McKesson is a healthcare services and information technology company with a market capitalization of $69.7 ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.Zacks Premium also includes the Zacks Style Scores.What a ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use a v ...

JHVEPhoto/iStock Editorial via Getty Images McKesson (NYSE:MCK) published their Q3 FY24 earnings on February 7th, reporting 15% topline growth and 12.2% adjusted EPS growth. I highlighted their growth opportunities in GLP-1 medications and their significant share buyback program in my introductory coverage. I maintain a 'Strong Buy' rating with a fair value of $660 per share. Strong GLP-1 Growth and Prior Authorization Network In Q3 FY24, McKesson delivered 15% revenue growth on a constant currency basi ...

McKesson Corporation (MCK) reported third-quarter fiscal 2024 adjusted earnings per share (EPS) of $7.74, which beat the Zacks Consensus Estimate of $7.05 by 9.8%. The bottom line also improved 12% on a year-over-year basis.GAAP EPS was $4.42, down 42% from the year-ago quarter’s level. The significant decline was due to the provision of bad debts worth $515 million for uncollected trade accounts receivable related to the bankruptcy of Rite Aid Corporation. Moreover, the company recorded a pre-tax benefit o ...